CTW09.19-15. BD
Courtesy of BDCourtesy of BD

    A frontline fighter in the war against microbes.

    The bugs that make us sick are increasingly resistant to the drugs we’ve used (and misused) to fight them. By one estimate, antimicrobial resistance (AMR) will cause the deaths of 10 million people annually by 2050. BD’s products, including its test to rapidly detect drug-resistant tuberculosis and its infection-prevention equipment, are tools to combat AMR. BD also trains health workers to quickly and precisely diagnose and treat infection. In Uganda, with BD’s help, turnaround time for a TB test has fallen from three weeks to three days, reducing chances that a patient will go untreated or be given the wrong drug.

    Company Information

    HeadquartersFranklin Lakes, N.J.
    Impact SegmentPublic Health/Nutrition
    IndustryMedical Products and Equipment
    CEOVincent Forlenza
    Company TypePublic
    Prior Year Rank-
    Revenues ($M) (Last Fiscal Year)$15,983
    Profits ($M) (Last Fiscal Year)$311
    Market Value ($M) as of 8/12/19$67,262